Clinical Trial

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product (romosozumab) until the last protocol-specified dose or ended investigational product early.
Protocol Amendment History 3 changes
notable Primary completion moved earlier: 2028-05-21 -> 2028-04-19 2026-06-23
minor Completion moved earlier: 2028-05-21 -> 2028-04-19 2026-06-23
critical Recruitment opened 2026-04-01
Trial Details
NCT Number NCT07366086
Lead Sponsor Amgen
Conditions Osteogenesis Imperfecta
Enrollment 71 participants
Start Date 2026-03-18
Primary Completion 2028-04-19 (estimated)
Study Completion 2028-04-19 (estimated)
Updated on ClinicalTrials.gov 2026-06-22